It was shown that P144 blocks TGF-β1 biological activity in different in vitro and in vivo models34,65–67 and it currently is the drug candidate Disitertide®, which is being tested for pathological skin fibrosis, such as scleroderma. Here, TGFB1 is linked to scleroderma.